QT Interval Prolongation and Second-line Antituberculosis Medicines in Children: An Update and Practical Considerations for Noncardiologists

Pediatr Infect Dis J. 2023 Mar 1;42(3):e80-e83. doi: 10.1097/INF.0000000000003742. Epub 2023 Feb 3.
No abstract available

MeSH terms

  • Antitubercular Agents* / adverse effects
  • Child
  • Electrocardiography*
  • Humans
  • Long QT Syndrome* / chemically induced

Substances

  • Antitubercular Agents